Refer to the respective prescribing information for bevacizumab, paclitaxel, and carboplatin for recommended dosing information TECENTRIQ in combination with nab-paclitaxel and carboplatin. Induction phase followed by chemotherapy-free infusions with TECENTRIQ.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECENTRIQ safely and effectively. See full prescribing information for TECENTRIQ. mg every 3 weeks, or 1680 mg every 4 weeks. TECENTRIQ (atezolizumab) injection, for intravenous use Initial U.S. Approval: 2024
Tecentriq and bevacizumab. Refer to the bevacizumab Product Information for full prescribing information on the risks of bleeding events
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TECENTRIQ HYBREZA safely and effectively. See full prescribing information for TECENTRIQ HYBREZA. TECENTRIQ HYBREZATM (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use Initial U.S. Approval: 2024
Full prescribing information for Tecentriq Hybreza will be posted on Drugs@FDA. The approval was made on Septem. The content in
(Tecentriq) plus paclitaxel in treatment-naïve patients with prescribing information, the regulatory agency wrote in their alert.
Recommendations from the TECENTRIQ (atezolizumab) Prescribing Information 1. No dose reduction for TECENTRIQ is recommended. In general, withhold TECENTRIQ for severe (grade 3) immune-mediated ARs.
There was a recent update to the TECENTRIQ (atezolizumab) Prescribing Information that impacted the dosing regimens for certain indications.
Description. Atezolizumab (Tecentriq) is a programmed death-ligand 1 (PD Tecentriq Prescribing Information. South San Francisco, CA: Genentech, Inc
Comments